Vanguard Capital Management’s Cadrenal Therapeutics CVKD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$18.2K Sell
16,859
-33,278
-66% -$60.4K ﹤0.01% 3989
2026
Q2
$167K Buy
50,137
+4,936
+11% +$23.4K ﹤0.01% 3834
2026
Q1
$231K Hold
45,201
– – ﹤0.01% 3781

Other funds holding CVKD

Vanguard Capital Management's CVKD Position: Q3 2026 in Review

Vanguard Capital Management reduced its Cadrenal Therapeutics (CVKD) stake by 66% in Q3 2026, selling an estimated $60.4K and leaving 16,859 shares worth $18.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3989.

Vanguard Capital Management first reported a position in CVKD in Q1 2026 and has held it in 3 quarters since. The position peaked at $231K in Q1 2026. 26 funds tracked by Wall St. Rank hold CVKD as of Q3 2026.

  • Vanguard Capital Management held 16,859 shares of Cadrenal Therapeutics worth $18.2K as of Q3 2026.
  • Vanguard Capital Management sold 33,278 Cadrenal Therapeutics shares in Q3 2026, an estimated $60.4K.
  • Cadrenal Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3989 holding.
  • Vanguard Capital Management first reported a position in Cadrenal Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Cadrenal Therapeutics position peaked at $231K in Q1 2026.
  • 26 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.